Shahneen K Sandhu
Overview
Explore the profile of Shahneen K Sandhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Atkinson V, Lo S, Guminski A, Sandhu S, Brown M, et al.
Lancet Oncol
. 2025 Feb;
26(3):320-330.
PMID: 39978375
Background: Patients with melanoma brain metastases respond well to immunotherapy, but long-term comparative survival data are scarce. We aimed to assess the efficacy of ipilimumab plus nivolumab versus nivolumab alone...
2.
Conduit C, Inderjeeth A, Allen R, Martin A, Parulekar W, Mulroe E, et al.
Future Oncol
. 2025 Jan;
21(6):627-636.
PMID: 39819293
No abstract available.
3.
Sweeney C, Martin A, Stockler M, Begbie S, Cheung L, Chi K, et al.
Lancet Oncol
. 2023 Mar;
24(4):323-334.
PMID: 36990608
Background: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report...
4.
Siva S, Bressel M, Wood S, Shaw M, Loi S, Sandhu S, et al.
Eur Urol
. 2021 Dec;
81(4):364-372.
PMID: 34953600
Background: Stereotactic ablative body radiotherapy (SABR) is an option for oligometastatic clear cell renal cell carcinoma (ccRCC) but is limited by a lack of prospective clinical trial data. Objective: The...
5.
Lozano R, Lorente D, Aragon I, Romero-Laorden N, Nombela P, Mateo J, et al.
Cancers (Basel)
. 2021 Jun;
13(10).
PMID: 34066080
Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not...
6.
Sweeney C, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S, et al.
Eur Urol
. 2021 May;
80(3):275-279.
PMID: 34030924
Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic disease and often have a low burden...
7.
Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S, et al.
N Engl J Med
. 2019 Jun;
381(2):121-131.
PMID: 31157964
Background: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or...
8.
Lee R, Zhang L, Berger A, Lawrence M, Song J, Niranjan B, et al.
Neoplasia
. 2019 Mar;
21(4):389-400.
PMID: 30901730
Approximately 50% of prostate cancers harbor the TMPRSS2:ERG fusion, resulting in elevated expression of the ERG transcription factor. Despite the identification of this subclass of prostate cancers, no personalized therapeutic...
9.
Raghu D, Paul P, Gulati T, Deb S, Khoo C, Russo A, et al.
Oncotarget
. 2017 May;
8(26):42939-42948.
PMID: 28477016
Prostate cancer (PC) is the most common cancer in men. Elevated levels of E3 ligase, E6-Associated Protein (E6AP) were previously linked to PC, consistent with increased protein expression in a...
10.
Scher H, Heller G, Molina A, Attard G, Danila D, Jia X, et al.
J Clin Oncol
. 2015 Mar;
33(12):1348-55.
PMID: 25800753
Purpose: Trials in castration-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for survival. We evaluated circulating tumor cell (CTC) enumeration as a surrogate outcome measure....